Arcus Biosciences, Inc.
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimabā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.00
Price+4.78%
$1.14
1Y
Price
Market Cap
$2.517b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-776.5%
EBITDA Margin-752.9%
Net Profit Margin-811.8%
Free Cash Flow Margin-776.5%
EBITDA Margin-752.9%
Net Profit Margin-811.8%
Free Cash Flow MarginRevenue
$236m
-4.4%
1y CAGR+37.3%
3y CAGR+29.1%
5y CAGREarnings
-$369m
-4.5%
1y CAGR-7.1%
3y CAGR-9.1%
5y CAGREPS
-$3.17
+3.7%
1y CAGR+7.7%
3y CAGR+2.8%
5y CAGRBook Value
$524m
$997m
Assets$473m
Liabilities$100m
DebtDebt to Assets
10.0%
-0.3x
Debt to EBITDAFree Cash Flow
-$489m
-1.0%
1y CAGR-43.1%
3y CAGR-76.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company